Claims for Patent: 7,537,916

Summary for Patent: 7,537,916

Title:	Efficient production of F(ab\').sub.2 fragments in mammalian cells
Abstract:	The present invention provides immortalized eukaryotic cells and methods useful for the production of immunologically active bivalent antibody fragments, such as F(ab\').sub.2 fragments. The methods and cells of the invention result in a desirable ratio of bivalent to monovalent antibody fragments.
Inventor(s):	Jones; David Halford Ashton (London, GB), Bout; Abraham (Moerkapelle, NL)
Assignee:	Crucell Holland B.V. (Leiden, NL)
Application Number:	12/070,145
Patent Claims:	1. A process for producing a F(ab').sub.2 fragment in a ratio of at least 1:1 with a corresponding F(ab') fragment by the recombiant expression from a cell, process comprising the steps of: providing a cell deposited at the European Collection of Cell Cultures ("ECACC") under number 96022940, said cell further comprising: one or more nucleic acids comprising sequences capable of driving expression operably linked to nucleotide sequences encoding F(ab').sub.2 fragments; culturing the cell in a suitable medium; and expressing the one or more nucleic acids to produce from the cell the F(ab').sub.2 fragment, wherein the F(ab').sub.2 fragment and the corresponding F(ab') fragment are secreted from the cell in a ratio of at least 1:1. 2. The process of claim 1, further comprising purifying the F(ab').sub.2 fragment. 3. The process of claim 1, wherein the F(ab').sub.2 fragment and the F(ab') fragment are secreted from the cell in a ratio of at least 2:1. 4. The process of claim 1, wherein the F(ab').sub.2 fragment and the F(ab') fragment are secreted from the cell in a ratio of at least 3:1. 5. The process of claim 1, wherein the sequences capable of driving expression comprise a nucleic acid sequence from a cytomegalovirus (CMV) immediate early gene enhancer/promoter. 6. The process of claim 1, wherein the nucleotide sequences encoding the F(ab').sub.2 fragments comprise at least one intron. 7. The process of claim 1, wherein the F(ab').sub.2 fragments' antigen binding regions are linked by at least one, but not more than 10 disulfide bonds. 8. The process of claim 7, wherein the antigen binding regions are linked by one or two disulfide bonds. 9. A method for improving a ratio of expressed F(ab').sub.2 fragments to F(ab') fragments by recombinant expression from cells as compared to expression from Chinese Hamster Ovary (CHO) cells, the process comprising: providing a cell deposited at the European Collection of Cell Cultures ("ECACC") under number 96022940 having one or more recombinant nucleic acids comprising sequences capable of driving expression operably linked to nucleotide sequences encoding F(ab').sub.2 fragments; culturing the cell in a suitable medium; and expressing the one or more nucleic acids to produce from the cell the F(ab').sub.2 fragment, so as to improve the ratio of expression F(ab').sub.2 fragments to F(ab') fragments to a ratio of at least 1:1.

Details for Patent 7,537,916

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-12-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-12-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-12-17